184 related articles for article (PubMed ID: 35399923)
1. Bone Mineral Density Assessment by Quantitative Computed Tomography in Glucocorticoid-Treated Boys With Duchenne Muscular Dystrophy: A Linear Mixed-Effects Modeling Approach.
Liu C; Yang DD; Zhang L; Lei XG; Jia FL; Liao Y; Chen XJ; Ning G; Luo W; Qu HB
Front Endocrinol (Lausanne); 2022; 13():860413. PubMed ID: 35399923
[TBL] [Abstract][Full Text] [Related]
2. Reduced bone mineral density in adolescents with Duchenne Muscular Dystrophy (DMD) and scoliosis.
Tsaknakis K; Jäckle K; Lüders KA; Lorenz HM; Braunschweig L; Hell AK
Osteoporos Int; 2022 Sep; 33(9):2011-2018. PubMed ID: 35583603
[TBL] [Abstract][Full Text] [Related]
3. Bone density and bone health alteration in boys with Duchenne Muscular Dystrophy: a prospective observational study.
Suthar R; Reddy BVC; Malviya M; Sirari T; Attri SV; Patial A; Tageja M; Didwal G; Khandelwal NK; Saini AG; Saini L; Sahu JK; Dayal D; Sankhyan N
J Pediatr Endocrinol Metab; 2021 May; 34(5):573-581. PubMed ID: 33838091
[TBL] [Abstract][Full Text] [Related]
4. Bone health measures in glucocorticoid-treated ambulatory boys with Duchenne muscular dystrophy.
Tian C; Wong BL; Hornung L; Khoury JC; Miller L; Bange J; Rybalsky I; Rutter MM
Neuromuscul Disord; 2016 Nov; 26(11):760-767. PubMed ID: 27614576
[TBL] [Abstract][Full Text] [Related]
5. Different bone health progression patterns and early-stage risk marker in glucocorticoid-treated ambulatory Duchenne muscular dystrophy.
Zhou L; Zhou H; Xu H; Sun X; Chen X; Fan P; Cai X; Wang Q
Osteoporos Int; 2024 Jun; 35(6):997-1005. PubMed ID: 38277031
[TBL] [Abstract][Full Text] [Related]
6. Risk factors associated with prevalent vertebral fractures in Duchenne muscular dystrophy.
Phung K; McAdam L; Ma J; McMillan HJ; Jackowski S; Scharke M; Matzinger MA; Shenouda N; Koujok K; Jaremko JL; Smit K; Walker S; Hartigan C; Khan N; Konji VN; MacLeay L; Page M; Sykes E; Robinson ME; Alos N; Cummings EA; Ho J; Sbrocchi AM; Stein R; Saleh D; Craven BC; Dang UJ; Siminoski K; Rauch F; Ward LM
Osteoporos Int; 2023 Jan; 34(1):147-160. PubMed ID: 36342539
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness of Neridronate in the Management of Bone Loss in Patients with Duchenne Muscular Dystrophy: Results from a Pilot Study.
Moretti A; Liguori S; Paoletta M; Gimigliano F; Iolascon G
Adv Ther; 2022 Jul; 39(7):3308-3315. PubMed ID: 35614293
[TBL] [Abstract][Full Text] [Related]
8. Randomized Controlled Trial Evaluating the Use of Zoledronic Acid in Duchenne Muscular Dystrophy.
Zacharin M; Lim A; Gryllakis J; Siafarikas A; Jefferies C; Briody J; Heather N; Pitkin J; Emmanuel J; Lee KJ; Wang X; Simm PJ; Munns CF
J Clin Endocrinol Metab; 2021 Jul; 106(8):2328-2342. PubMed ID: 33954789
[TBL] [Abstract][Full Text] [Related]
9. Effects of Traction on Interpretation of Lumbar Bone Mineral Density in Patients with Duchenne Muscular Dystrophy: A New Measurement Method and Diagnostic Criteria Based on Comparison of Dual-Energy X-Ray Absorptiometry and Quantitative Computed Tomography.
Lee JS; Kim K; Jeon YK; Kim J; Jung DH; Kim SH; Shin MJ; Shin YB
J Clin Densitom; 2020; 23(1):53-62. PubMed ID: 30143440
[TBL] [Abstract][Full Text] [Related]
10. Bone health in Duchenne muscular dystrophy: clinical and biochemical correlates.
Catalano A; Vita GL; Bellone F; Sframeli M; Distefano MG; La Rosa M; Gaudio A; Vita G; Morabito N; Messina S
J Endocrinol Invest; 2022 Mar; 45(3):517-525. PubMed ID: 34524678
[TBL] [Abstract][Full Text] [Related]
11. Oral bisphosphonate treatment in patients with Duchenne muscular dystrophy on long term glucocorticoid therapy.
Tian C; Wong BL; Hornung L; Khoury JC; Rybalsky I; Shellenbarger KC; Rutter MM
Neuromuscul Disord; 2020 Jul; 30(7):599-610. PubMed ID: 32680651
[TBL] [Abstract][Full Text] [Related]
12. Low bone density and bone metabolism alterations in Duchenne muscular dystrophy: response to calcium and vitamin D treatment.
Bianchi ML; Morandi L; Andreucci E; Vai S; Frasunkiewicz J; Cottafava R
Osteoporos Int; 2011 Feb; 22(2):529-39. PubMed ID: 20458570
[TBL] [Abstract][Full Text] [Related]
13. Growth, bone health & ambulatory status of boys with DMD treated with daily vs. intermittent oral glucocorticoid regimen.
Crabtree NJ; Adams JE; Padidela R; Shaw NJ; Högler W; Roper H; Hughes I; Daniel A; Mughal MZ
Bone; 2018 Nov; 116():181-186. PubMed ID: 30055340
[TBL] [Abstract][Full Text] [Related]
14. Alendronate in the treatment of low bone mass in steroid-treated boys with Duchennes muscular dystrophy.
Hawker GA; Ridout R; Harris VA; Chase CC; Fielding LJ; Biggar WD
Arch Phys Med Rehabil; 2005 Feb; 86(2):284-8. PubMed ID: 15706555
[TBL] [Abstract][Full Text] [Related]
15. Effects of Bisphosphonates on Osteoporosis Induced by Duchenne Muscular Dystrophy: A Prospective Study.
Zheng WB; Dai Y; Hu J; Zhao DC; Wang O; Jiang Y; Xia WB; Xing XP; Li M
Endocr Pract; 2020 Dec; 26(12):1477-1485. PubMed ID: 33471740
[TBL] [Abstract][Full Text] [Related]
16. Bone density and alendronate effects in Duchenne muscular dystrophy patients.
Houston C; Mathews K; Shibli-Rahhal A
Muscle Nerve; 2014 Apr; 49(4):506-11. PubMed ID: 23835890
[TBL] [Abstract][Full Text] [Related]
17. Can radial bone mineral density predict spinal bone mineral density in patients with advanced Duchenne muscular dystrophy?
Kim E; Cho HE; Jung JH; Lee JW; Choi WA; Kang SW
Medicine (Baltimore); 2018 Oct; 97(40):e12303. PubMed ID: 30290594
[TBL] [Abstract][Full Text] [Related]
18. Bone microarchitectural alterations in boys with Duchenne muscular dystrophy on long-term glucocorticoid treatment.
Tung JY; Lam TP; Chan SH
J Bone Miner Metab; 2021 Jul; 39(4):606-611. PubMed ID: 33400004
[TBL] [Abstract][Full Text] [Related]
19. The time to and determinants of first fractures in boys with Duchenne muscular dystrophy.
Ma J; McMillan HJ; Karagüzel G; Goodin C; Wasson J; Matzinger MA; DesClouds P; Cram D; Page M; Konji VN; Lentle B; Ward LM
Osteoporos Int; 2017 Feb; 28(2):597-608. PubMed ID: 27774565
[TBL] [Abstract][Full Text] [Related]
20. The relationship of bone mineral density and vitamin D levels with steroid use and ambulation in patients with Duchenne muscular dystrophy.
Sertpoyraz FM; Tiftikçioğlu Bİ
Turk J Phys Med Rehabil; 2019 Sep; 65(3):216-221. PubMed ID: 31663069
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
